299 related articles for article (PubMed ID: 17971587)
1. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Burke M; Anderson JR; Kao SC; Rodeberg D; Qualman SJ; Wolden SL; Meyer WH; Breitfeld PP;
J Clin Oncol; 2007 Nov; 25(31):4909-13. PubMed ID: 17971587
[TBL] [Abstract][Full Text] [Related]
2. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcoma.
Wolden SL; La TH; LaQuaglia MP; Meyers PA; Kraus DH; Wexler LH
Cancer; 2003 Jan; 97(1):179-85. PubMed ID: 12491519
[TBL] [Abstract][Full Text] [Related]
4. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
Dantonello TM; Int-Veen C; Harms D; Leuschner I; Schmidt BF; Herbst M; Juergens H; Scheel-Walter HG; Bielack SS; Klingebiel T; Dickerhoff R; Kirsch S; Brecht I; Schmelzle R; Greulich M; Gadner H; Greiner J; Marky I; Treuner J; Koscielniak E
J Clin Oncol; 2009 Mar; 27(9):1446-55. PubMed ID: 19224858
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of intensified chemotherapy in children with advanced rhabdomyosarcoma (clinical groups III and IV). The Intergroup Rhabdomyosarcoma Study (IRS) Committee of the Cancer and Leukemia Group B Children's Cancer Study Group, Southwest Oncology Group.
Raney RB; Gehan EA; Maurer HM; Newton WA; Ragab AH; Ruymann FB; Sutow WW; Tefft M
Cancer Clin Trials; 1979; 2(1):19-28. PubMed ID: 391431
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
Spunt SL; Smith LM; Ruymann FB; Qualman SJ; Donaldson SS; Rodeberg DA; Anderson JR; Crist WM; Link MP
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6072-9. PubMed ID: 15447992
[TBL] [Abstract][Full Text] [Related]
7. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
[TBL] [Abstract][Full Text] [Related]
8. [Results of treatment of rhabdomyosarcomas (RMS) in children. A report of the Cooperative Soft Tissue Sarcoma Study (CWS-81) of the Society of Pediatric Oncology].
Treuner J; Kaatsch P; Anger Y; Seipp A; Spaar HJ; Gerein V; Suder J; Niethammer D
Klin Padiatr; 1986; 198(3):208-17. PubMed ID: 3523026
[TBL] [Abstract][Full Text] [Related]
9. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?
Arndt CA; Donaldson SS; Anderson JR; Andrassy RJ; Laurie F; Link MP; Raney RB; Maurer HM; Crist WM
Cancer; 2001 Jun; 91(12):2454-68. PubMed ID: 11413538
[TBL] [Abstract][Full Text] [Related]
10. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors.
Carli M; Colombatti R; Oberlin O; Bisogno G; Treuner J; Koscielniak E; Tridello G; Garaventa A; Pinkerton R; Stevens M
J Clin Oncol; 2004 Dec; 22(23):4787-94. PubMed ID: 15570080
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997.
Blakely ML; Andrassy RJ; Raney RB; Anderson JR; Wiener ES; Rodeberg DA; Paidas CN; Lobe TE; Crist WM;
J Pediatr Surg; 2003 Mar; 38(3):347-53. PubMed ID: 12632347
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
[TBL] [Abstract][Full Text] [Related]
13. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.
Wolden SL; Anderson JR; Crist WM; Breneman JC; Wharam MD; Wiener ES; Qualman SJ; Donaldson SS
J Clin Oncol; 1999 Nov; 17(11):3468-75. PubMed ID: 10550144
[TBL] [Abstract][Full Text] [Related]
14. Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee.
Cecchetto G; Carretto E; Bisogno G; Dall'Igna P; Ferrari A; Scarzello G; Donfrancesco A; Alaggio R; Indolfi P; Carli M
Pediatr Blood Cancer; 2008 Nov; 51(5):593-7. PubMed ID: 18668515
[TBL] [Abstract][Full Text] [Related]
15. Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary?
Schuck A; Mattke AC; Schmidt B; Kunz DS; Harms D; Knietig R; Treuner J; Koscielniak E
J Clin Oncol; 2004 Jan; 22(1):143-9. PubMed ID: 14701776
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
[TBL] [Abstract][Full Text] [Related]
17. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
Smith LM; Anderson JR; Qualman SJ; Crist WM; Paidas CN; Teot LA; Pappo AS; Link MP; Grier HE; Wiener ES; Breneman JC; Raney RB; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Oct; 19(20):4058-64. PubMed ID: 11600608
[TBL] [Abstract][Full Text] [Related]
18. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood.
Douglas JG; Arndt CA; Hawkins DS
Eur J Cancer; 2007 Apr; 43(6):1045-50. PubMed ID: 17368885
[TBL] [Abstract][Full Text] [Related]
19. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.
Rosenberg AR; Anderson JR; Lyden E; Rodeberg DA; Wolden SL; Kao SC; Parham DM; Arndt C; Hawkins DS
Eur J Cancer; 2014 Mar; 50(4):816-23. PubMed ID: 24361229
[TBL] [Abstract][Full Text] [Related]
20. Radiation therapy combined with systemic chemotherapy of rhabdomyosarcoma in children: local control in patients enrolled in the Intergroup Rhabdomyosarcoma Study.
Tefft M; Lindberg RD; Gehan EA
Natl Cancer Inst Monogr; 1981 Apr; (56):75-81. PubMed ID: 7029298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
